I-Pennsaid yisisombululo se-NSAID esiphezulu esathola imvume ye-FDA ngo-November 4, 2009, ukuphatha ubuhlungu kanye nezimpawu ezihlobene ne- knee osteoarthritis . Igama elijwayelekile le-Pennsaid yi-diclofenac sodium. I-Pennsaid yasungulwa yi-Nuvo Research Inc. Lena inguqulo ye-diclofenac, eyatholakala njengephilisi.
I-Pennsaid isebenza kanjani?
Zonke izidakamizwa ezingekho-steroidal anti-inflammatory (NSAIDs) zisebenza ngendlela efanayo.
Zivimbela i-cyclooxygenase, i-enzyme ehlose ukukhiqizwa kwe-prostaglandins, okuyisisekelo sezithunywa zamakhemikhali esiqhumeni sokuvuvukala. Ngokuvimbela leyo enzyme, ama-NSAID aholela emazingeni e-prostaglandin futhi avuvukala kancane. Ngeshwa, i-prostaglandin iyasiza kwezinye imisebenzi yomzimba, ngakho-ke ama-NSAID anemiphumela emibi emibi. Ngokuphawulekayo, i-prostaglandins iyinhloko ekukhiqizeni i-membrane yamangqamuzana esiswini okubalulekile ekuvikeleni uketshezi kwesisu kusuka ku-asidi. Ama-NSAID, ngokunciphisa i-prostaglandin, okuholela ekutheni ukuphazamiseka kwalesi sithinte sokuvikela futhi kungabangela ukucasuka kwesisu kanye nezilonda.
Imfundiso yokusebenzisa i-NSAID yama-topical yukuthi ukusetshenziswa kwesidakamizwa sendawo kuyoholela ekunciphiseni ukuvuvukala, nokunciphisa okuhambisanayo nobuhlungu endaweni yesicelo, kodwa isidakamizwa ngeke sifinyelele ezingxenyeni eziphakeme zegazi ukuze kuholele imiphumela emibi yesistimu ezifana nezilonda zesisu.
Eqinisweni, ucwaningo luye lwabonisa ukuthi nge-topical application yama-NSAID amazinga e-systemic omuthi angama-5% kuphela okuyikho ngaphakathi kwamathisiphi lapho kusetshenziswa khona izidakamizwa.
Imiphumela emibi efana ne-NSAID yomlomo
Ukusetshenziswa kwama-NSAID e-topical ekwelapheni i-knee-osteoarthritis inikeza izinzuzo ezithile zokuphepha emathunjini eziningana ezibhedlela.
Indlela yokwenza lezi zinzuzo njengoba kuchaziwe ngenhla. Ukwelashwa kwendawo kungase kuphephe futhi kubekezeleleke uma kuqhathaniswa nama-NSAID omlomo.
Ikhono lezenzakalo ezimbi ezinjengezilonda, ukuphuma kwamathumbu emathunjini , kanye nezingozi zenhliziyo zikhona kodwa zingaphansi uma kuqhathaniswa nefilisi yalezi zidakamizwa.
Umphumela ovame kakhulu ohlangene ne-Pennsaid ubumile obuphansi noma ukucasuka lapho kusetshenziswa khona.
Isebenza?
Ukubuyekezwa kwamuva okwenziwe yi-Cochrane Collaboration kubhekwe izifundo ezingu-61 eziphenya ukuthi ngabe ama-NSAID angokwezifiso asebenza yini. Ngamafuphi, impendulo inguyebo. Uma kuhlanganiswa idatha kuzo zonke izifundo, abantu abangaba ngu-75% babhekana nokukhululeka okukhulu kwemisipha yomzimba / isisindo (ukukhululeka okuphawulekayo okuchazwe njengokunciphisa ubuhlungu ngesigamu) uma usebenzisa i-diclofenac yama-topical, lokhu kuhluke kubantu abangaba ngu-50% wathola indawo ye-placebo.
Imithombo:
Ukubuyekezwa kwe-Cochrane ye-Topical NSAIDs
> http://www.cochrane.org/CD007402/SYMPT_topical-non-steroidal-anti-inflammatory-drugs-for-acute-musculoskeletal-pain-in-adults
I-FDA ivumela i-Pennsaid. Drugs.com.
http://www.drugs.com/newdrugs/fda-approves-pennsaid-topical-solution-1758.html
I-Pennsaid. NUVO